ZA200600806B - Viral vectors - Google Patents
Viral vectorsInfo
- Publication number
- ZA200600806B ZA200600806B ZA200600806A ZA200600806A ZA200600806B ZA 200600806 B ZA200600806 B ZA 200600806B ZA 200600806 A ZA200600806 A ZA 200600806A ZA 200600806 A ZA200600806 A ZA 200600806A ZA 200600806 B ZA200600806 B ZA 200600806B
- Authority
- ZA
- South Africa
- Prior art keywords
- viral vectors
- gene encoding
- gene
- encoding
- protein
- Prior art date
Links
- 239000013603 viral vector Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 abstract 1
- 101150027249 RL1 gene Proteins 0.000 abstract 1
- 230000007910 cell fusion Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/869—Herpesviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/869—Herpesviral vectors
- C12N15/8695—Herpes simplex virus-based vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317511.4A GB0317511D0 (en) | 2003-07-25 | 2003-07-25 | Viral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200600806B true ZA200600806B (en) | 2007-05-30 |
Family
ID=27772737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200600806A ZA200600806B (en) | 2003-07-25 | 2004-07-26 | Viral vectors |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7981669B2 (enExample) |
| EP (1) | EP1648481B1 (enExample) |
| JP (1) | JP4767168B2 (enExample) |
| KR (2) | KR20120006582A (enExample) |
| CN (1) | CN1829523B (enExample) |
| AT (1) | ATE440611T1 (enExample) |
| AU (1) | AU2004261037B2 (enExample) |
| BR (1) | BRPI0412845A (enExample) |
| CA (1) | CA2533338C (enExample) |
| DE (1) | DE602004022823D1 (enExample) |
| ES (1) | ES2331075T3 (enExample) |
| GB (2) | GB0317511D0 (enExample) |
| IL (1) | IL173295A0 (enExample) |
| MX (1) | MXPA06000876A (enExample) |
| PL (1) | PL1648481T3 (enExample) |
| WO (1) | WO2005011715A1 (enExample) |
| ZA (1) | ZA200600806B (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0107736B8 (pt) * | 2000-01-21 | 2021-05-25 | Biovex Ltd | cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1 |
| GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| US8039587B2 (en) | 2003-10-24 | 2011-10-18 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| EP2114420B1 (en) * | 2007-02-16 | 2016-01-27 | Virttu Biologics Limited | Herpes simplex viruses and methods of viral replication |
| CA2687301C (en) * | 2007-05-09 | 2016-08-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses type-1 for treatment of cancers |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| RS58146B1 (sr) | 2011-09-08 | 2019-02-28 | Univ New York | Onkolitički herpes simpleks virus i njegova terapeutska upotreba |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| WO2015061386A1 (en) | 2013-10-24 | 2015-04-30 | Amgen Inc. | Injector and method of assembly |
| CA2926110C (en) | 2013-10-24 | 2023-05-23 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| EP3785749A1 (en) | 2014-05-07 | 2021-03-03 | Amgen Inc. | Autoinjector with shock reducing elements |
| MX2016015926A (es) | 2014-06-03 | 2017-06-26 | Amgen Inc | Sistema de suministro de farmacos y metodo de uso. |
| MX392725B (es) | 2014-10-14 | 2025-03-24 | Amgen Inc | Dispositivo de inyeccion de farmaco con indicadores visuales y audibles. |
| EP3848072A1 (en) | 2014-12-19 | 2021-07-14 | Amgen Inc. | Drug delivery device with proximity sensor |
| JP2017538512A (ja) | 2014-12-19 | 2017-12-28 | アムジエン・インコーポレーテツド | ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置 |
| US10583245B2 (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| JP2018512184A (ja) | 2015-02-27 | 2018-05-17 | アムジエン・インコーポレーテツド | 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置 |
| EP3307330B1 (en) | 2015-06-15 | 2021-03-10 | New York University | Method of treatment using oncolytic viruses |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
| WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
| EP3400293B2 (en) | 2016-01-08 | 2023-07-12 | Replimune Limited | Modified oncolytic virus |
| US11200298B2 (en) | 2016-03-15 | 2021-12-14 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
| WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| ES2959783T3 (es) | 2016-05-13 | 2024-02-28 | Amgen Inc | Conjunto de cubierta protectora de vial |
| WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
| WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| EP3570917A1 (en) | 2017-01-17 | 2019-11-27 | Amgen Inc. | Injection devices and related methods of use and assembly |
| US11369736B2 (en) | 2017-02-17 | 2022-06-28 | Amgen Inc. | Cannula insertion and retraction mechanisms |
| MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
| EP3592403B1 (en) | 2017-03-06 | 2025-08-20 | Amgen Inc. | Drug delivery device with activation prevention feature |
| MX2019010543A (es) | 2017-03-07 | 2019-10-21 | Amgen Inc | Insercion de agujas por sobrepresion. |
| JP2020509837A (ja) | 2017-03-09 | 2020-04-02 | アムジエン・インコーポレーテツド | 薬剤送達装置のための挿入機構 |
| LT3600491T (lt) | 2017-03-28 | 2023-10-10 | Amgen Inc. | Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas |
| CA3061982A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| EP3634546A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Torque driven drug delivery device |
| CN107354136A (zh) * | 2017-06-15 | 2017-11-17 | 杭州睿可特生物科技有限公司 | 重组单纯疱疹病毒及其制备方法和应用 |
| JP7195276B2 (ja) | 2017-06-22 | 2022-12-23 | アムジエン・インコーポレーテツド | デバイス起動による衝突／衝撃の低減 |
| MX2019015479A (es) | 2017-06-23 | 2020-02-20 | Amgen Inc | Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador. |
| ES2972207T3 (es) | 2017-07-14 | 2024-06-11 | Amgen Inc | Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble |
| US11672733B2 (en) | 2017-07-21 | 2023-06-13 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
| JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
| EP3658203B2 (en) | 2017-07-25 | 2025-10-01 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
| WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
| US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
| EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
| EP3694578B1 (en) | 2017-10-09 | 2025-09-24 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
| WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
| ES2994389T3 (en) | 2017-11-06 | 2025-01-23 | Amgen Inc | Drug delivery device with placement and flow sensing |
| MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
| CN111225696B (zh) | 2017-11-10 | 2023-07-18 | 安进公司 | 用于药物递送装置的柱塞 |
| CA3079540A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| CN112351804A (zh) | 2018-07-24 | 2021-02-09 | 安进公司 | 用于施用药物的输送装置 |
| US12115360B2 (en) | 2018-07-24 | 2024-10-15 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
| MX2021000748A (es) | 2018-07-24 | 2021-03-26 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
| CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
| MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
| EP3856283A1 (en) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| TWI857975B (zh) | 2018-10-02 | 2024-10-11 | 美商安進公司 | 具有內部力傳遞的用於藥物遞送之注射系統 |
| MX2021003491A (es) | 2018-10-05 | 2021-06-18 | Amgen Inc | Dispositivo de administracion de farmacos con indicador de dosis. |
| EA202191038A1 (ru) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | Способ платформенной сборки для устройства доставки лекарственного средства |
| EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
| US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| EP3873563A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| JP7510952B2 (ja) | 2019-04-24 | 2024-07-04 | アムジエン・インコーポレーテツド | シリンジ滅菌確認アセンブリ及び方法 |
| AU2020337250A1 (en) | 2019-08-23 | 2022-03-03 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
| WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| BR112023024278A2 (pt) | 2021-05-21 | 2024-01-30 | Amgen Inc | Método de otimizar uma receita de enchimento para um recipiente de fármacos |
| WO2024071397A1 (ja) | 2022-09-30 | 2024-04-04 | 国立大学法人 東京大学 | Ｉｌ１３ｒａ２に標的化した単純ヘルペスウイルス及び抗ｉｌ１３ｒａ２抗体またはその抗原結合断片 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328688A (en) * | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| GB9102126D0 (en) | 1991-01-31 | 1991-03-13 | Smithkline Beecham Biolog | Novel vaccine |
| US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| GB9423663D0 (en) | 1994-11-23 | 1995-01-11 | Cantab Pharma Res | Viral preparations, immunogens, and vaccines |
| NL9500216A (nl) * | 1995-02-06 | 1996-09-02 | Bio Pharma Sciences Bv | Farmaceutische samenstelling voor de behandeling van herpes. |
| IL118942A (en) | 1995-07-27 | 2002-09-12 | American Cyanamid Co | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| ATE241994T1 (de) | 1996-01-25 | 2003-06-15 | Univ Glasgow | Hsv-mutant-1716 zur behandlung von mesotheliomen |
| US5824318A (en) * | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| US5876923A (en) * | 1996-07-26 | 1999-03-02 | Arch Development Corporation | Herpes simplex virus ICP4 as an inhibitor of apoptosis |
| GB9615794D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
| JPH1087503A (ja) * | 1996-09-06 | 1998-04-07 | Nippon Chem Res Kk | 神経系腫瘍細胞のアポトーシス剤 |
| GB9700411D0 (en) | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US20030219409A1 (en) * | 1997-01-10 | 2003-11-27 | Biovex Limited | Eukaryotic gene expression cassette and uses thereof |
| GB9704046D0 (en) | 1997-02-27 | 1997-04-16 | Univ Leeds | Arrestable therapeutic |
| WO1998040492A1 (en) * | 1997-03-11 | 1998-09-17 | Cambridge Genetics Limited | Compositions and methods for elimination of unwanted cells |
| US6051428A (en) | 1997-03-21 | 2000-04-18 | Sloan-Kettering Institute For Cancer Research | Rapid production of autologous tumor vaccines |
| US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| AU8605598A (en) * | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| GB9810904D0 (en) | 1998-05-20 | 1998-07-22 | Univ London | Mutant herpes simplex viruses and uses thereof |
| US20040063094A1 (en) * | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| GB0009079D0 (en) | 2000-04-12 | 2000-05-31 | Neurovex Ltd | Herpes viruses for immune modulation |
| US6713067B2 (en) * | 1998-07-31 | 2004-03-30 | Biovex Limited | Herpes viruses for immune modulation |
| GB9816781D0 (en) | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| GB9816856D0 (en) | 1998-08-03 | 1998-09-30 | Univ London | Cell lines for virus growth |
| JP2003535565A (ja) | 1998-12-31 | 2003-12-02 | アーチ ディベロプメント コーポレイション | 新生物疾患の治療に有用な組換え単純ヘルペスウイルス |
| US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| EP1190040B1 (en) * | 1999-06-08 | 2007-08-22 | UAB Research Foundation | Herpes simplex virus expressing interleukin-12 gene and and its use for treating cancer |
| GB9930419D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| GB9930418D0 (en) * | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| BRPI0107736B8 (pt) | 2000-01-21 | 2021-05-25 | Biovex Ltd | cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1 |
| GB0001476D0 (en) | 2000-01-21 | 2000-03-15 | Neurovex Ltd | Herpes virus strains |
| US7063851B2 (en) * | 2000-04-12 | 2006-06-20 | Biovex Limited | Herpes viruses for immune modulation |
| FI113931B (fi) * | 2002-05-23 | 2004-06-30 | Oplayo Oy | Menetelmä ja järjestelmä HCVQ-vektorikirjaston muodostamiseksi |
| GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
-
2003
- 2003-07-25 GB GBGB0317511.4A patent/GB0317511D0/en not_active Ceased
-
2004
- 2004-07-26 AT AT04743547T patent/ATE440611T1/de not_active IP Right Cessation
- 2004-07-26 JP JP2006520905A patent/JP4767168B2/ja not_active Expired - Lifetime
- 2004-07-26 ES ES04743547T patent/ES2331075T3/es not_active Expired - Lifetime
- 2004-07-26 ZA ZA200600806A patent/ZA200600806B/xx unknown
- 2004-07-26 DE DE602004022823T patent/DE602004022823D1/de not_active Expired - Lifetime
- 2004-07-26 GB GB0416628A patent/GB2405406B/en not_active Expired - Lifetime
- 2004-07-26 KR KR1020127000220A patent/KR20120006582A/ko not_active Ceased
- 2004-07-26 CN CN2004800215652A patent/CN1829523B/zh not_active Expired - Lifetime
- 2004-07-26 KR KR1020067001697A patent/KR101177659B1/ko not_active Expired - Lifetime
- 2004-07-26 MX MXPA06000876A patent/MXPA06000876A/es active IP Right Grant
- 2004-07-26 BR BRPI0412845-1A patent/BRPI0412845A/pt not_active Application Discontinuation
- 2004-07-26 AU AU2004261037A patent/AU2004261037B2/en not_active Expired
- 2004-07-26 WO PCT/GB2004/003217 patent/WO2005011715A1/en not_active Ceased
- 2004-07-26 CA CA2533338A patent/CA2533338C/en not_active Expired - Lifetime
- 2004-07-26 EP EP04743547A patent/EP1648481B1/en not_active Expired - Lifetime
- 2004-07-26 PL PL04743547T patent/PL1648481T3/pl unknown
-
2006
- 2006-01-23 IL IL173295A patent/IL173295A0/en active IP Right Grant
- 2006-01-25 US US11/339,804 patent/US7981669B2/en not_active Expired - Lifetime
-
2010
- 2010-02-19 US US12/708,692 patent/US8679830B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004261037B2 (en) | 2009-09-24 |
| KR20060039013A (ko) | 2006-05-04 |
| WO2005011715A1 (en) | 2005-02-10 |
| HK1083595A1 (en) | 2006-07-07 |
| CN1829523A (zh) | 2006-09-06 |
| US8679830B2 (en) | 2014-03-25 |
| BRPI0412845A (pt) | 2006-09-26 |
| EP1648481B1 (en) | 2009-08-26 |
| US20060188480A1 (en) | 2006-08-24 |
| GB0317511D0 (en) | 2003-08-27 |
| GB0416628D0 (en) | 2004-08-25 |
| KR20120006582A (ko) | 2012-01-18 |
| CA2533338A1 (en) | 2005-02-10 |
| KR101177659B1 (ko) | 2012-08-27 |
| ES2331075T3 (es) | 2009-12-21 |
| CN1829523B (zh) | 2010-05-12 |
| US20100143309A1 (en) | 2010-06-10 |
| ATE440611T1 (de) | 2009-09-15 |
| CA2533338C (en) | 2012-05-08 |
| GB2405406A (en) | 2005-03-02 |
| US7981669B2 (en) | 2011-07-19 |
| JP2006528484A (ja) | 2006-12-21 |
| MXPA06000876A (es) | 2006-08-23 |
| IL173295A0 (en) | 2006-06-11 |
| EP1648481A1 (en) | 2006-04-26 |
| AU2004261037A1 (en) | 2005-02-10 |
| JP4767168B2 (ja) | 2011-09-07 |
| GB2405406B (en) | 2008-01-02 |
| PL1648481T3 (pl) | 2010-01-29 |
| DE602004022823D1 (de) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2405406B (en) | Viral vectors | |
| GB2374873A (en) | Herpes virus strains | |
| WO2003068923A3 (en) | Signal for packaging of influenza virus vectors | |
| WO2005056807A3 (en) | Bovine adeno-associated viral (baav) vector and uses thereof | |
| AU2003238456A1 (en) | Viral vector | |
| EP0757717A4 (en) | PAPILLOMAVIRUS VACCINE | |
| WO2001064920A3 (en) | Hybrid expression of neisserial proteins | |
| DE60029230D1 (de) | Dipeptidyl-peptidasen | |
| AU2002339119A1 (en) | Sequence of the photorhabdus luminescens strain tt01 genome and uses | |
| EP1461079B8 (en) | Human immunodeficiency virus envelope glycoprotein mutants and uses thereof | |
| WO2002006457A3 (en) | Novel lipase genes | |
| WO2004046365A3 (en) | Interferon-alpha polypeptides and conjugates | |
| AU2003225544A1 (en) | Recombinant bovine immunodeficiency virus based gene transfer system | |
| WO2001049721A3 (en) | Bacterial genes and proteins that are essential for cell viability and their uses | |
| AU5322800A (en) | Cloned genone of infectious hepatitis c virus of genotype 2a and uses thereof | |
| AU2003273983A1 (en) | Viral vectors and the use of the same for gene therapy | |
| AU2511901A (en) | Basolateral sorting signal and inhibitors thereof | |
| WO2001064912A3 (en) | Triazine degrading enzymes | |
| AU2001238064A1 (en) | 18477, a human protein kinase and uses therefor | |
| AU4903099A (en) | Targeted integration into chromosomes using retroviral vectors | |
| WO2003093438A3 (en) | Human adipocyte cell populations and methods for identifying modulators of same | |
| WO2006127822A3 (en) | Scytovirin domain 1 related polypeptides | |
| WO2003087294A3 (de) | Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression | |
| WO2005059101A3 (en) | Novel sodium channel | |
| WO2003046138A3 (en) | Genetically stable expression vector |